Business
Faron to Participate at Canaccord Conference
Faron to Participate at Canaccord Conference.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\nFaron Pharmaceuticals Ltd.\n (\"Faron\" or \"the Company\")\n \n Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference\n \nPress release, August 02, 2023\n \n· Management to present on Thursday, August 10 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts\n· Presentation will highlight recent updated positive Phase I/II BEXMAB data of bexmarilimab in relapsed/refractory AML and MDS\n \nTURKU, Finland / BOSTON, Massachusetts - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's Chief Executive Officer, Dr. Markku Jalkanen, and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, Massachusetts, in Room Abigail Adams C.\n \nThe Company will discuss the most recent positive clinical data from the Company's ongoing Phase I/II BEXMAB study, investigating bexmarilimab, Faron's wholly owned immunotherapy asset, in combination with standard of care (SoC) in the aggressive hematological malignancies of r/r acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA). The Company's filing of its first Biologics License Application (BLA) to the FDA is planned for H1 2025.\n \nA live webcast of the fireside chat can be found here and in the Investor Relations section of Faron's website at https://www.faron.com/investors/results-presentations. Following the completion of the event, a webcast replay of the fireside chat will be available on the website for 90 days.\n \nFor more information please contact:\n \nInvestor Contact\n \nLifeSci Advisors\nDaniel Ferry\nManaging Director\[email protected]\n+1 (617) 430-7576\n \nMedia Contact\n \nFaron Pharmaceuticals\nJennifer C. Smith-Parker\nHead of Communications\[email protected]\n \nCairn Financi...